Rubric Capital Management LP Purchases 421,347 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Rubric Capital Management LP grew its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 12.7% during the first quarter, Holdings Channel reports. The institutional investor owned 3,750,000 shares of the company’s stock after purchasing an additional 421,347 shares during the quarter. Kiniksa Pharmaceuticals International accounts for 1.9% of Rubric Capital Management LP’s holdings, making the stock its 12th largest holding. Rubric Capital Management LP’s holdings in Kiniksa Pharmaceuticals International were worth $180,562,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Qube Research & Technologies Ltd raised its stake in Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after acquiring an additional 653,236 shares during the period. Cubist Systematic Strategies LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 213.2% in the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after purchasing an additional 447,536 shares in the last quarter. Spruce Street Capital LP bought a new stake in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $17,943,000. Nomura Holdings Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at approximately $15,421,000. Finally, Logos Global Management LP bought a new position in Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $14,438,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, insider John F. Paolini sold 58,424 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $53.71, for a total value of $3,137,953.04. Following the transaction, the insider owned 65,623 shares of the company’s stock, valued at approximately $3,524,611.33. This represents a 47.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $54.02, for a total value of $2,623,481.30. Following the completion of the sale, the chief executive officer owned 48,565 shares in the company, valued at $2,623,481.30. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 131,674 shares of company stock valued at $7,094,671. Insiders own 51.98% of the company’s stock.

Wall Street Analysts Forecast Growth

KNSA has been the subject of a number of recent research reports. The Goldman Sachs Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, July 23rd. Canaccord Genuity Group raised their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Wedbush lifted their price target on Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the company an “outperform” rating in a research report on Monday, June 29th. Wells Fargo & Company lifted their price target on Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Finally, Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $68.00.

Kiniksa Pharmaceuticals International Trading Up 1.1%

KNSA stock opened at $63.53 on Tuesday. The firm has a 50 day moving average of $57.07 and a 200-day moving average of $50.18. The firm has a market capitalization of $4.89 billion, a P/E ratio of 70.59 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 12 month low of $26.51 and a 12 month high of $67.53.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The business had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. During the same quarter in the prior year, the firm posted $0.11 EPS. Kiniksa Pharmaceuticals International’s revenue was up 55.5% on a year-over-year basis. Sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.25 EPS for the current year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.